{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:33:36Z","timestamp":1786116816979,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008966","name":"Francophone Society for Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eprac.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:07:48Z","timestamp":1771315668000},"page":"788-794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistence of Residual Insulin Secretion in Long-Standing Cystic Fibrosis-Related Diabetes"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-4373","authenticated-orcid":false,"given":"Irene","family":"Aguilera Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Mifsud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fideline","family":"Bonnet-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Camus-Bablon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Larger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eprac.2026.02.008_bib1","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.008_bib2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"108","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.008_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis: role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eprac.2026.02.008_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.008_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2011.11.001","article-title":"Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus","volume":"11","author":"Hillman","year":"2012","journal-title":"J Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.008_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.008_bib7","doi-asserted-by":"crossref","first-page":"E851","DOI":"10.1210\/jc.2010-2460","article-title":"Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis - effects of pancreatic enzyme supplementation","volume":"96","author":"Kuo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.008_bib8","author":"Dimeglio"},{"key":"10.1016\/j.eprac.2026.02.008_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet Elsevier B"},{"key":"10.1016\/j.eprac.2026.02.008_bib10","doi-asserted-by":"crossref","first-page":"111839","DOI":"10.1016\/j.diabres.2024.111839","article-title":"Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice","volume":"216","author":"Aguilera Garc\u00eda","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.008_bib11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cystic Fibrosis"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.008_bib12","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.008_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"23","author":"Nielsen","year":"2024","journal-title":"J Cystic Fibrosis"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.008_bib14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2337\/dc23-0380","article-title":"Cystic fibrosis\u2013related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes","volume":"46","author":"Putman","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2026.02.008_bib15","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.2337\/db18-0279","article-title":"Increased B-cell workload modulates proinsulin-to-insulin ratio in humans","volume":"67","author":"Mezza","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.eprac.2026.02.008_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.trsl.2019.08.001","article-title":"Abnormalities in proinsulin processing in islets from individuals with longstanding T1D","volume":"213","author":"Sims","year":"2019","journal-title":"Transl Res"},{"issue":"7","key":"10.1016\/j.eprac.2026.02.008_bib17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.eprac.2026.02.008_bib18","series-title":"R pachage \u201ccorrrplot\u201d: Visualization of a Correlation Matrix (Version 0.92)","author":"Taiyun","year":"2021"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.008_bib19","doi-asserted-by":"crossref","first-page":"e15012","DOI":"10.1111\/dme.15012","article-title":"Fasting and meal-stimulated serum C-peptide in long-standing type 1 diabetes mellitus","volume":"40","author":"Vollenbrock","year":"2023","journal-title":"Diabetic Med"},{"issue":"18","key":"10.1016\/j.eprac.2026.02.008_bib20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.008_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.tem.2009.12.010","article-title":"Cytokine production by islets in health and diabetes: cellular origin, regulation and function","volume":"21","author":"Donath","year":"2010","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.008_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet Interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that May contribute to \u03b2-Cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.008_bib23","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/diagnostics11030572","article-title":"Cystic Fibrosis-Related Diabetes (CFRD): overview of associated genetic factors","volume":"11","author":"Iafusco","year":"2021","journal-title":"Diagnostics"},{"issue":"8","key":"10.1016\/j.eprac.2026.02.008_bib24","doi-asserted-by":"crossref","first-page":"e98240","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.eprac.2026.02.008_bib25","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2337\/db17-1006","article-title":"\u03b2-Cell DNA damage response promotes islet inflammation in type 1 diabetes","volume":"67","author":"Horwitz","year":"2018","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.eprac.2026.02.008_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00281-019-00745-4","article-title":"Islet inflammation in type 2 diabetes","volume":"41","author":"B\u00f6ni-Schnetzler","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.008_bib27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-3476(97)70282-8","article-title":"Insulin resistance is associated with decreased clinical status in cystic fibrosis","volume":"130","author":"Hardin","year":"1997","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.eprac.2026.02.008_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.008_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.008_bib30","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes John Wiley Sons Inc"},{"key":"10.1016\/j.eprac.2026.02.008_bib31","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.008_bib32","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cystic Fibrosis"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.008_bib33","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.008_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2431-14-70","article-title":"Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus","volume":"14","author":"Ballmann","year":"2014","journal-title":"BMC Pediatr"},{"issue":"7","key":"10.1016\/j.eprac.2026.02.008_bib35","doi-asserted-by":"crossref","first-page":"dgaa167","DOI":"10.1210\/clinem\/dgaa167","article-title":"Semaglutide in cystic fibrosis-related diabetes","volume":"105","author":"Gnanapragasam","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.02.008_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.008_bib37","first-page":"100375","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2026.02.008_bib38","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2337\/db22-0399","article-title":"Effects of GLP-1 and GIP on islet function in Glucose-Intolerant, pancreatic-insufficient cystic fibrosis","volume":"71","author":"Nyirjesy","year":"2022","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2026.02.008_bib39","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2026.02.008_bib40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3390\/biomedicines11061754","article-title":"Continuous glucose monitoring as an additional tool in early cystic fibrosis-related diabetes monitoring and in evaluation of short-term sitagliptin response","volume":"11","author":"Sebastian-Valles","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.eprac.2026.02.008_bib41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jcf.2024.06.007","article-title":"Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: a single centre experience","volume":"23","author":"Santhakumar","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.eprac.2026.02.008_bib42","first-page":"100276","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.008_bib43","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1111\/dom.16516","article-title":"Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: rationale and emerging evidence","volume":"27","author":"Assalia Naffa","year":"2025","journal-title":"Diabetes Obes Meta"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:03:15Z","timestamp":1786017795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26007858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1530891X26007858"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.008","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of Residual Insulin Secretion in Long-Standing Cystic Fibrosis-Related Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}